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The renin-angiotensin system (RAS) plays a potential role in the development of end-organ damage, and tissue RAS
activation has been suggested as a risk factor of several diseases including diabetes. So far, using animal disease
models, we have shown molecular mechanisms, in which tissue RAS stimulates retinal angiogenesis, and the critical
roles of (pro)renin receptor [(P)RR] in retinal RAS activation and its concurrent intracellular signal transduction,
referred to as the receptor-associated prorenin system (RAPS). Moreover, we recently reported that the protein
levels of prorenin and soluble (P)RR increased in the vitreous fluids obtained from patients with proliferative
diabetic retinopathy (PDR), suggesting the association of (P)RR with vascular endothelial growth factor (VEGF)-driven
angiogenic activity in human PDR, and also showed a close relationship between the vitreous renin activity and
VEGF-induced pathogenesis of diabetic retinopathy. Our data using animal disease models and human clinical
samples suggest that both vitreous RAS and retinal RAPS play critical roles in the molecular pathogenesis of
diabetic retinopathy.
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Diabetic retinopathy (DR) is one of the severe complica-
tions of diabetes and leading cause of severe vision loss
and blindness when it progresses to the stage of prolifer-
ative DR (PDR) characterized by fibrovascular prolifera-
tion. Fibrovascular tissue develops by the extension of
retinal angiogenesis into the vitreous cavity, and forma-
tion of the fibrovascular tissue results in severe compli-
cations, such as tractional retinal detachment and
vitreous hemorrhage. Several growth factors and cyto-
kines are involved in the molecular pathogenesis of* Correspondence: kanda@med.hokudai.ac.jp
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growth factor (VEGF) has been considered as the major
angiogenic and proinflammatory factor in PDR [1–3].
VEGF plays important roles in normal physiology such
as in embryogenesis, endometrial maturation, and
wound healing. However, it also causes profound patho-
genesis complicating diabetes and cancer. Tumor growth
requires new vessel formation, which is driven predom-
inantly by VEGF, the most potent angiogenic factor and
the principal target for anti-angiogenic therapy [4]. We
previously revealed a significant contribution of
VEGF165 isoform to angiogenic activity in PDR, show-
ing that fibrovascular tissues co-expressing VEGF recep-
tor (VEGFR)-2 and neuropilin (NRP) 1, the specific
receptor for VEGF165, were highly vascularized [5–7].le is distributed under the terms of the Creative Commons Attribution 4.0
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hesion molecules and subsequently stimulates leukocyte
infiltration leading to the development of retinal angio-
genesis [5–7].
The renin-angiotensin system (RAS), a known import-
ant controller of systemic blood pressure (circulatory
RAS), plays distinct roles in inflammation and patho-
logical vascular conditions in organs including the brain,
eye, heart, liver, and kidney (tissue RAS) [8]. Tissue RAS
acts in a paracrine fashion and regulates various
biological and pathological events such as cell signaling,
apoptosis, proliferation, angiogenesis, immune re-
sponses, and extracellular matrix formation [9–11]. In
this review, we focus on the relationship between dia-
betic retinopathy and tissue RAS and suggest a novel
concept for the molecular pathogenesis of tissue RAS in
the vitreous, referred to as “vitreous RAS.”
Vitreous renin-angiotensin system and retinal
receptor-associated prorenin system in diabetic
retinopathy
Several types of organ damage are known to result from ac-
tivation of tissue RAS. As concerns its relationship with the
eye, pharmacological blockade of angiotensin-converting
enzyme (ACE) or angiotensin II type 1 receptor (AT1R) re-
sulted in beneficial effects on the incidence and progression
of DR in several clinical trials including the EUCLID study,
DIRECT-Prevent 1, DIRECT-Protect 1, DIRECT-Protect 2,
and the RAS study [12–15]. We unraveled the molecular
mechanisms in which tissue RAS causes retinal inflamma-
tion and angiogenesis in the murine model of endotoxin-
induced uveitis, strepotozotocin-induced diabetes, and
laser-induced choroidal neovascularization [16–18] and the
critical role of (pro)renin receptor [(P)RR] in retinal RAS
activation [19–22]. Tissue RAS is initiated by prorenin
binding with (P)RR to acquire renin activity, which also
causes RAS-independent signal transduction in cells bear-
ing (P)RR. Prorenin binding to (P)RR causes renin activity
through the conformational change of prorenin (non-pro-
teolytic activation of prorenin causing tissue RAS) instead
of the conventional proteolysis of the prorenin prosegment
by processing enzymes (proteolytic activation of prorenin
causing circulatory RAS). In addition to tissue RAS activa-
tion, prorenin binding to (P)RR activates RAS-independent
signal transduction via mitogen-activated protein kinases
including extracellular signal-regulated kinase (ERK) 1/2
pathway, which has been shown to contribute to organ
damage. (P)RR can bind to both prorenin and renin, but
the binding affinity of prorenin is much higher than that of
renin [23]. The (P)RR-mediated dual activation of tissue
RAS and RAS-independent signaling pathways, referred to
as the receptor-associated prorenin system (RAPS), was
shown to be involved in the molecular pathogenesis of ocu-
lar disorders including retinal inflammation and choroidalneovascularization [20, 21, 24], both of which are due to
the upregulated expression of VEGF in the downstream of
retinal and choroidal RAPS, respectively.
Remarkably, (P)RR was reported to undergo cleavage by
proteases to generate a soluble form of (P)RR [s(P)RR],
whereas it still has a capability for non-proteolytic activa-
tion of prorenin, causing the conversion of angiotensinogen
(AGT) to angiotensin I (Ang I) in vitro [25]. We have
shown that s(P)RR, prorenin, activated prorenin, and VEGF
protein levels together with renin activity levels in vitreous
fluids were significantly higher in PDR eyes compared to
non-diabetic controls [26, 27]. Increased protein levels of
s(P)RR in PDR eyes, released from neovascular endothelial
cells in fibrovascular tissues, were significantly correlated
with vitreous prorenin, activated prorenin, and VEGF pro-
tein levels and the vascular density of fibrovascular tissues
[26]. Interestingly, renin activity levels also significantly cor-
related with the vitreous protein levels of s(P)RR, prorenin,
activated prorenin, and VEGF [27]. These data indicate that
the vitreous renin activity stems from s(P)RR-mediated
non-proteolytic activation of prorenin, suggesting the sig-
nificant role of (P)RR in the pathogenesis of PDR. Indeed,
(P)RR and RAS components were expressed in diabetic fi-
brovascular tissues, human retinal cell lines, and normal
ocular tissues [26, 28–30], and the vitreous levels of prore-
nin and angiotensin II (Ang II) were shown to be elevated
in PDR eyes [31–34]. Furthermore, a close link between the
vitreous renin activity and VEGF protein levels validates
our concept of vitreous RAS that contributes to the angio-
genic activity of DR. Consequently, in concert with vitreous
RAS due to s(P)RR (Fig. 1a) [27], retinal RAPS due to
membrane-type (i.e., full-length) (P)RR [26] (Fig. 1b) is
thought to regulate VEGF expression in DR. Moreover, we
have recently shown that RAPS is involved in the molecular
pathogenesis of organ damage, such as inflammation,
angiogenesis, and fibrosis, including conjunctival lymph-
oma [28] and other ocular disorders (under review).
Although we have shown the significant role of (P)RR
signaling via ERK [21, 26] as well as AT1R signaling via
nuclear factor (NF)-kB [16] in the upregulation of VEGF
expression, it is difficult to determine the ratio of in-
volvement with the angiogenic activity in human PDR.
Cleavage enzymes for processing full-length (P)RR to
s(P)RR include the proprotein convertase furin [35] and
ADAM (a disintegrin and metalloproteinase) 19 [36],
both of which proved to be present in endothelial cells
in the fibrovascular tissue in PDR [26]. Gene expression
and enzymatic activity of these proteases in the neovas-
cular endothelial cells are likely to define the contribu-
tion ratio between vitreous RAS and retinal RAPS.
Investigation into the biochemical regulation of furin
and ADAM19 is required in the future to further eluci-
date (P)RR-related molecular pathogenesis of diabetic
retinopathy.
a b
Fig. 1 A schema showing the significant involvement of retinal RAPS (a) and vitreous RAS (b) with the VEGF-driven pathogenesis of diabetic retinopathy.
Vitreous RAS is caused by s(P)RR, whereas retinal RAPS depends on membrane-type (P)RR (modified from Kanda et al. [27]). ACE angiotensin-converting
enzyme, AGT angiotensinogen, Ang I angiotensin I, Ang II angiotensin II, AT1R angiotensin II type 1 receptor, ERK extracellular signal-regulated kinase, NF-kB
nuclear factor-kB, (P)RR (pro)renin receptor
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RAS may be attributed in part to a possibility of revising
the current surgical indication and concept of vitrec-
tomy for DR. In clinical setting, retinal surgeons remove
the vitreous from PDR eyes because of (1) vitreous
hemorrhage from newly formed vessels disturbing the
visual axis and (2) tractional retinal detachment in which
the retina is elevated by the vitreous that functions as
the scaffold of the fibrovascular proliferative tissue
originating from retinal vessels. These two major classic
indications to the advanced stage have long been applied
in terms of a mechanical or physical cue. In contrast,
our data on vitreous renin activity indicate the possibility
of the vitreous per se as the amplifier of the molecular
pathogenesis of PDR. Retinal surgeons frequently en-
counter surgical cases where diabetic macular edema, a
consequence of VEGF-induced vascular hyperpermeabi-
liy, is diminished soon after vitrectomy. This is explained
at least in part by the pathological concept of vitreous
RAS, the driving force of the downstream AT1R/nuclear
factor-kB (NF-kB)/VEGF axis responsible for the patho-
genesis of diabetic retinopathy (Fig. 1). It is reasonable,
therefore, to think that the vitreous is not just the reser-
voir of detrimental cytokines but the factory of patho-
genic RAS components. In this sense, vitrectomy
procedure harbors a biochemical implication, which may
expand the current surgical strategy to earlier interven-
tion for broader indications to reduce the vitreous RAS-derived capability of producing VEGF and other several
cytokines.
Conclusions
Our findings may not only lead to a new understanding
of the molecular pathogenesis that implies a close link
among the vitreous RAS, retinal RAPS, and VEGF-
induced pathogenesis of diabetic retinopathy but also
activate the clinical research in the surgical as well as
medical point of view, thus contributing to further im-
provement of visual prognosis in patients with DR.
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